$15.09
1.69% day before yesterday
NYSE, Sep 06, 10:10 pm CET
ISIN
US28414H1032
Symbol
ELAN

Elanco Animal Health, Inc. Stock price

$15.09
+2.64 21.20% 1M
-0.96 5.98% 6M
+0.19 1.28% YTD
+3.12 26.07% 1Y
-19.06 55.81% 3Y
-12.26 44.83% 5Y
-20.91 58.08% 10Y
NYSE, Closing price Fri, Sep 06 2024
-0.26 1.69%
ISIN
US28414H1032
Symbol
ELAN

Key metrics

Market capitalization $7.46b
Enterprise Value $12.72b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 29.93
EV/Sales (TTM) EV/Sales 2.83
P/S ratio (TTM) P/S ratio 1.66
P/B ratio (TTM) P/B ratio 1.26
Revenue growth (TTM) Revenue growth 3.74%
Revenue (TTM) Revenue $4.49b
EBIT (operating result TTM) EBIT $300.00m
Free Cash Flow (TTM) Free Cash Flow $425.00m
Cash position $416.00m
EPS (TTM) EPS $-2.55
P/E forward 21.67
P/S forward 1.68
EV/Sales forward 2.87
Short interest 3.92%
Show more

Is Elanco Animal Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Elanco Animal Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Elanco Animal Health, Inc. forecast:

8x Buy
62%
5x Hold
38%

Analyst Opinions

13 Analysts have issued a Elanco Animal Health, Inc. forecast:

Buy
62%
Hold
38%

Financial data from Elanco Animal Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
4,492 4,492
4% 4%
100%
- Direct Costs 2,555 2,555
8% 8%
57%
1,937 1,937
1% 1%
43%
- Selling and Administrative Expenses 624 624
5% 5%
14%
- Research and Development Expense 341 341
7% 7%
8%
972 972
6% 6%
22%
- Depreciation and Amortization 672 672
2% 2%
15%
EBIT (Operating Income) EBIT 300 300
15% 15%
7%
Net Profit -1,255 -1,255
1,194% 1,194%
-28%

In millions USD.

Don't miss a Thing! We will send you all news about Elanco Animal Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Elanco Animal Health, Inc. Stock News

Neutral
PRNewsWire
11 days ago
GREENFIELD, Ind. , Aug. 28, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference, September 4-5, 2024.
Neutral
PRNewsWire
19 days ago
Company's broad spectrum parasiticide on-track for October U.S. approval and first quarter 2025 launch GREENFIELD, Ind. , Aug. 20, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its review of all major and minor technical sections for Credelio Quattro, and the final 60-day administrative review is und...
Positive
Seeking Alpha
22 days ago
After an acquisition of Bayer Animal Health in 2020, Elanco has made progress in paying down debt. Robust pipeline with six potential blockbuster products to be launched in 2024 and 2025. Improving cash flow and financial metrics.
More Elanco Animal Health, Inc. News

Company Profile

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Head office United States
CEO Jeffrey Simmons
Employees 9,800
Founded 1954
Website www.elanco.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today